Aerpio Licenses Development, Sales Rights of IBD Candidate AKB-4924 to Gossamer Bio
News
Aerpio Pharmaceuticals announced a licensing agreement with Gossamer Bio to develop and commercialize Aerpio’s investigative therapy AKB-4924 as a treatment for inflammatory bowel disease (IBD). AKB-4924 (to be changed to GB004) is a hypoxia-inducible factor-1 alpha ... Read more